Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
Terminated
Oncopeptides AB
Phase 1/Phase 2
2013-07-01
The study will explore escalating doses of melflufen in combination with dexamethasone in
small groups of patients to find the maximum tolerated dose of melflufen. That dose will then
be used to determine the efficacy and safety profile of melflufen in combination with
dexamethasone in a larger group of patients.
A Study of Melphalan Flufenamide (Melflufen) in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients
Active, not recruiting
Precision For Medicine
Phase 2
2016-12-28
This study will evaluate melflufen in combination with dexamethasone in the treatment of
relapsed refractory multiple myeloma in adult patients with disease refractory to
pomalidomide and/or an anti-CD38 monoclonal antibody. All patients in the study will be
treated with melflufen on Day 1 and dexamethasone on Days 1, 8, 15 and 22 of each 28-day
cycle.
A Study of Melphalan Flufenamide (Melflufen) in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients
Active, not recruiting
Precision Oncology
Phase 2
2016-12-28
This study will evaluate melflufen in combination with dexamethasone in the treatment of
relapsed refractory multiple myeloma in adult patients with disease refractory to
pomalidomide and/or an anti-CD38 monoclonal antibody. All patients in the study will be
treated with melflufen on Day 1 and dexamethasone on Days 1, 8, 15 and 22 of each 28-day
cycle.
A Study of Melphalan Flufenamide (Melflufen) in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients
Active, not recruiting
Oncopeptides AB
Phase 2
2016-12-28
This study will evaluate melflufen in combination with dexamethasone in the treatment of
relapsed refractory multiple myeloma in adult patients with disease refractory to
pomalidomide and/or an anti-CD38 monoclonal antibody. All patients in the study will be
treated with melflufen on Day 1 and dexamethasone on Days 1, 8, 15 and 22 of each 28-day
cycle.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
